TRACON Pharmaceuticals Inc

NASDAQ:TCON  
1.69
-0.06 (-3.16%)
Products

Tracon Pharmaceuticals Announces Fast Track Designation By The FDA For Envafolimab For The Treatment Of The Soft Tissue Sarcoma Subtypes Of Ups And Mfs

Published: 09/14/2022 13:01 GMT
TRACON Pharmaceuticals Inc (TCON) - Tracon Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of Ups and Mfs.
Tracon Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of Ups and Mfs.